ArticlePharmaceutical research2010
In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.
Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- PLGA-based long-acting injectable (LAI) formulations.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Size-Exclusion Chromatography-Electrospray-Ionization Mass Spectrometry To Characterize End Group and Chemical Distribution of Poly(lactide-Journal of the American Society for Mass Spectrometry · 2025Article
- PLGA Implants for Controlled Drug Delivery and Regenerative Medicine: Advances, Challenges, and Clinical Potential.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Development and Applications of PLGA Hydrogels for Sustained Delivery of Therapeutic Agents.Gels (Basel, Switzerland) · 2024Review
- Article
- Quality-by-Design Based Development of Doxycycline Hyclate-Loaded Polymeric Microspheres for Prolonged Drug Release.AAPS PharmSciTech · 2024Article
- The Impact of Post-Processing Temperature on PLGA Microparticle Properties.Pharmaceutical research · 2023Article
- Application of a Customised Franz-Type Cell Coupled with HPTLC to Monitor the Timed Release of Bioactive Components in Complex Honey Matrices.Methods and protocols · 2023Article
- Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Correlative Image-Based Release Prediction and 3D Microstructure Characterization for a Long Acting Parenteral Implant.Pharmaceutical research · 2021Article
- Poly(lactic-co-glycolic acid) Nanoparticles Encapsulating the Prenylated Flavonoid, Xanthohumol, Protect Corneal Epithelial Cells from Dry Eye Disease-Associated Oxidative Stress.Pharmaceutics · 2021Article
- Coupling the in vivo performance to the in vitro characterization of PLGA microparticles.International journal of pharmaceutics · 2021Article
- The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.Frontiers in pharmacology · 2021Review
- Article
- Vancomycin- and Poly(simvastatin)-Loaded Scaffolds with Time-Dependent Development of Porosity.ACS applied bio materials · 2019Article
- Butyl stearate prolongs the drug release period of isoperidone‑loaded poly (lactic‑co‑glycolic acid) microspheres: In vitro and in vivo investigation.Molecular medicine reports · 2019Article
- A method to slow down the ionization-dependent release of risperidone loaded in a thermoresponsive poly(N-acryloyl glycinamide) hydrogel.Drug delivery and translational research · 2017Article
- Encapsulation of Nicardipine Hydrochloride and Release from Biodegradable Poly(D,L-lactic-co-glycolic acid) Microparticles by Double Emulsion Process: Effect of Emulsion Stability and Different Parameters on Drug Entrapment.International journal of biomaterials · 2017Article
- Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.Pharmaceutical research · 2016Article
- In vitro-in vivo correlation for complex non-oral drug products: Where do we stand?Journal of controlled release : official journal of the Controlled Release Society · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeNonadherence to antipsychotic medications is a major obstacle preventing optimal outcomes for patients with schizophrenia. Extended release systems exist in the form of depot injections, but these formulations exhibit several disadvantages. To address these concerns, we previously demonstrated proof of concept for an antipsychotic implant containing risperidone and the biodegradable polymer poly(lactic-co-glycolic) acid (PLGA).
methodsWe build upon recently published data by utilizing a scalable single-screw extrusion system for the production of PLGA-risperidone implants. Implants were composed of 40% risperidone and 60% PLGA, with varying ratios of lactide to glycolide (50:50, 65:35, 75:25 or 85:15). Risperidone release was assessed in vitro and in vivo in rats, and Level A, B and C correlations (IVIVCs) attempted for all. Bioavailability was verified with locomotor testing
resultsLevel B analysis yielded the greatest correlation between in vitro and in vivo data (R (2) = 0.9425), while Level C yielded the lowest (R (2) = 0.8336). Although, based on qualitative results, a Level A correlation was not achieved, it did produce an R (2) of 0.9261. Locomotor testing demonstrated that peak serum concentrations coincide with significant reductions in activity.
conclusionData demonstrate the applicability of our modeling system and advance long-term, implantable antipsychotics toward clinical application.
Indexed as
Identifiers
20422263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.